| The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia |
| Young Joo Min, Cheol Won Suh, Keon Uk Park, Sung Soo Yoon, Chan Hyung Park, Hong Ghi Lee |
1Department of Internal Medicine, Ulsan University Hospital,University of Ulsan College of Medicine, Ulsan, Korea.
2Department of Medicine, Asan Medical Center, University ofUlsan College of Medicine, Korea.
3Department of Internal Medicine, Seoul National UniversityCollege of Medicine, Korea.
4Department of Medicine, Samsung Medical Center, SungkyunkwanUniversity School of Medicine, Seoul, Korea.mlee@smc.samsung.co.kr
|
|
Published online: February 28, 2003. |
|
|
|
| ABSTRACT |
PURPOSE:
This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML).
MATERIALS AND METHODS:
After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days.
RESULTS:
The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%).
CONCLUSION:
The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML. |
| Key words:
Acute myelogenous leukemia;rhG-CSF;Neutropenia |
|
PDF Links
Full text via DOI
Download Citation 
